Precision BioSciences, Inc. DTIL
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3,472.96% | -11.87% | -50.12% | -99.07% | -98.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3,472.96% | -11.87% | -50.12% | -99.07% | -98.56% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 3,472.96% | -11.87% | -50.12% | -99.07% | -98.56% |
| SG&A Expenses | -16.23% | -7.76% | -2.22% | -7.83% | -5.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.86% | -11.60% | -8.90% | -1.21% | -3.75% |
| Operating Income | 59.61% | 11.29% | -99.33% | -452.28% | -1,135.40% |
| Income Before Tax | 31.48% | -102.33% | -750.33% | -828.37% | -595.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.48% | -102.33% | -750.33% | -828.37% | -595.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.62% | -98.31% | -737.98% | -1,069.52% | -561.16% |
| EBIT | 59.61% | 11.29% | -99.33% | -452.28% | -1,135.40% |
| EBITDA | 60.14% | 8.91% | -122.69% | -634.12% | -3,981.85% |
| EPS Basic | 68.27% | -84.58% | -366.33% | -10,335.08% | -3,906.00% |
| Normalized Basic EPS | 68.58% | -72.74% | -339.23% | -1,553.89% | -2,367.37% |
| EPS Diluted | 68.18% | -82.09% | -371.23% | -16,484.02% | -4,490.79% |
| Normalized Diluted EPS | 68.50% | -70.40% | -343.24% | -1,640.87% | -2,162.98% |
| Average Basic Shares Outstanding | 128.38% | 110.97% | 87.48% | 72.16% | 79.23% |
| Average Diluted Shares Outstanding | 128.72% | 111.05% | 87.59% | 71.81% | 78.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |